Case Report : MPO-ANCA Associated Vasculitis After Pfizer-BioNTech COVID-19 mRNA Vaccination
Copyright by Società Italiana di Nefrologia SIN, Rome,Italy..
We report a case of MPO-anti-neutrophil cytoplasmic antibody ANCA-associated vasculitis, with pulmonary-renal syndrome, after the mRNA booster third dose vaccine Pfizer BioNTech against COVID-19 in 71-year-old Caucasian man with no specific past medical history. A kidney biopsy diagnosed ANCA-associated pauci-immune crescentic glomerulonephritis. Renal function and constitutional symptoms have been partially improved with treatment with dialysis, intravenous rituximab and steroid pulse therapy. No disease following either infection or vaccination with fourth dose against COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia - 40(2023), 4 vom: 31. Aug. |
| Sprache: |
Italienisch |
|---|
| Beteiligte Personen: |
Mazza, Fabio [VerfasserIn] |
|---|
| Themen: |
ANCA vasculitis |
|---|
| Anmerkungen: |
Date Completed 03.11.2023 Date Revised 03.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM364021098 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364021098 | ||
| 003 | DE-627 | ||
| 005 | 20231226094558.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ita c | ||
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM364021098 | ||
| 035 | |a (NLM)37910213 | ||
| 035 | |a (PII)2023-vol4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Mazza, Fabio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Case Report |b MPO-ANCA Associated Vasculitis After Pfizer-BioNTech COVID-19 mRNA Vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2023 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright by Società Italiana di Nefrologia SIN, Rome,Italy. | ||
| 520 | |a We report a case of MPO-anti-neutrophil cytoplasmic antibody ANCA-associated vasculitis, with pulmonary-renal syndrome, after the mRNA booster third dose vaccine Pfizer BioNTech against COVID-19 in 71-year-old Caucasian man with no specific past medical history. A kidney biopsy diagnosed ANCA-associated pauci-immune crescentic glomerulonephritis. Renal function and constitutional symptoms have been partially improved with treatment with dialysis, intravenous rituximab and steroid pulse therapy. No disease following either infection or vaccination with fourth dose against COVID-19 | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a ANCA vasculitis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a booster dose | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
| 700 | 1 | |a Cicciarelli, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Rubino, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Leopizzi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Di Maio, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Cerbelli, Bruna |e verfasserin |4 aut | |
| 700 | 1 | |a Tatangelo, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Palumbo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Cioffi, Ernesto Anselmo |e verfasserin |4 aut | |
| 700 | 1 | |a Simonelli, Roberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia |d 1997 |g 40(2023), 4 vom: 31. Aug. |w (DE-627)NLM093699778 |x 1724-5990 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:4 |g day:31 |g month:08 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 4 |b 31 |c 08 | ||